Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

Leukemia. 2017 Dec;31(12):2848-2850. doi: 10.1038/leu.2017.266. Epub 2017 Aug 18.

Authors

A Nazha¹, K Al-Issa¹, B K Hamilton¹, T Radivoyevitch², A T Gerds¹, S Mukherjee¹, V Adema², A Zarzour¹, N Abuhadra¹, B J Patel¹, C M Hirsch², A Advani¹, B Przychodzen², H E Carraway¹, J P Maciejewski², M A Sekeres¹

Affiliations

¹ Leukemia Program, Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
² Department of Translational Hematology and Oncology Research, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.

PMID: 28819282
DOI: 10.1038/leu.2017.266

No abstract available

MeSH terms

Adult
Aged
Aged, 80 and over
Female
Humans
Leukocytes, Mononuclear / drug effects
Leukocytes, Mononuclear / pathology
Male
Middle Aged
Mutation
Myelodysplastic Syndromes / drug therapy
Myelodysplastic Syndromes / pathology*
Prognosis
Young Adult